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Abstract
Human cytomegalovirus (CMV) is a herpes virus with poorly understood transmission
dynamics. Person-to-person transmission is thought to occur primarily through transfer of
saliva or urine, but no quantitative estimates are available for the contribution of different
infection routes. Using data from a large population-based serological study (n = 5,179), we
provide quantitative estimates of key epidemiological parameters, including the transmissi-
bility of primary infection, reactivation, and re-infection. Mixture models are fitted to age- and
sex-specific antibody response data from the Netherlands, showing that the data can be
described by a model with three distributions of antibody measurements, i.e. uninfected,
infected, and infected with increased antibody concentration. Estimates of seroprevalence
increase gradually with age, such that at 80 years 73% (95%CrI: 64%-78%) of females and
62% (95%CrI: 55%-68%) of males are infected, while 57% (95%CrI: 47%-67%) of females
and 37% (95%CrI: 28%-46%) of males have increased antibody concentration. Merging the
statistical analyses with transmission models, we find that models with infectious reactiva-
tion (i.e. reactivation that can lead to the virus being transmitted to a novel host) fit the data
significantly better than models without infectious reactivation. Estimated reactivation rates
increase from low values in children to 2%-4% per year in women older than 50 years. The
results advance a hypothesis in which transmission from adults after infectious reactivation
is a key driver of transmission. We discuss the implications for control strategies aimed at
reducing CMV infection in vulnerable groups.
Author summary
Human cytomegalovirus (CMV) is a herpes virus causing lifelong infection. In high-
income countries, the probability of infection increases gradually with age such that at old
age up to 100% of the population is infected. CMV is thought to be transmitted mainly by
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transfer of saliva or urine, but little quantitative evidence is available about the transmis-
sion dynamics. We analyze serological data to estimate age- and sex-specific rates of infec-
tion, re-infection, and reactivation. The analyses show that infectious reactivation (i.e.
reactivation of the virus in an infected person that is sufficient for it to be transmitted to
another person) is essential to explain the data. We propose that infectious reactivation in
adults is an important driver of transmission of CMV.
Introduction
Human cytomegalovirus (CMV) is a highly prevalent herpesvirus that infects between 30%
and 100% of persons in populations throughout the world [1]. Usually thought to be a rela-
tively benign persistent infection, CMV is able to cause serious disease in the immunocompro-
mised and offspring of pregnant women with an active infection [2–5]. CMV also has been
implicated in a variety of diseases in healthy persons [4, 6–8], and plays a role in aging of the
immune system [9–12], perhaps thereby reducing the effectiveness of vaccination in older per-
sons [13–15].
Although the importance of CMV to public health is acknowledged, and even though the
development and registration of a vaccine has been declared a priority [16, 17], little quantita-
tive information is available on the transmission dynamics of CMV. At present, the only popu-
lation-level data derive from serological studies, aiming to uncover which part of the
population is infected at what age. These studies show that i) a sizable fraction of infants is
infected perinatally (before 6 months of age), ii) seroprevalence increases gradually with age
and is usually higher in females than in males, and iii) the probability of seropositivity is associ-
ated with both ethnicity and socioeconomic status, with non-western ethnicity and lower
socioeconomic status being associated with higher rates of seropositivity [1, 18–21].
CMV infection has a profound impact on the human immune system. Most prominently, it
is able to mould the T cell immune repertoire, in particular by expansion of the CMV-specific
CD8+ memory T cell pool, a phenomenon called memory inflation [12]. Similar result have
been found for memory B cell immunity [22]. With regard to humoral immune responses,
high levels of CMV-specific IgG antibodies are increasingly considered a biomarker for lack of
control by the immune system of the host, and have been associated with high probability of
reactivation ([23, 24], see [12] and references therein). In view of this, it is not surprising that
evidence is accumulating of an association between high levels of CMV-specific IgG antibod-
ies, inflammation, vascular disease, and mortality [6, 7].
Person-to-person transmission of CMV from an infected to an uninfected person can
occur from a primary infected person, or from a person who is experiencing a reactivation epi-
sode or from a person who has been reinfected [4]. Here, we analyze data from a large-scale
serological study to obtain quantitative estimates of the relative importance of these transmis-
sion routes [21]. We fit mixture models linked to age- and sex-specific transmission models to
the data to study the ability of different hypotheses explaining the serological data. Specifically,
we quantify the incidence and transmissibility of primary infection, re-infection, and reactiva-
tion. Throughout, our premise is that measurements of antibody concentrations provide infor-
mation on whether or not a person has been infected, and whether or not re-infection or
reactivation have occurred. Persons with low measurements are considered uninfected (sus-
ceptible), while persons with intermediate and high antibody concentrations are infected with
and without subsequent re-infection or reactivation, respectively.
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The analyses show that infectious reactivation in adults is necessary to explain the data, and
is expected to be an important driver of transmission. The results have implications for control
of CMV by vaccination, but also in the broader context of T cell immune memory inflation,
vascular disease, and immunosenescence [12, 25, 26].
Methods
Ethics statement
The study was approved by the Medical Ethics Testing Committee of the foundation of thera-
peutic evaluation of medicines (METC-STEG) in Almere, the Netherlands (clinical trial num-
ber: ISRCTN 20164309). All participants or their legal representatives had given written
informed consent.
Study design
The analyses make use of sera from a cross-sectional population-based study carried out in the
Netherlands in 2006-2007. Details have been published elsewhere [21, 27]. Briefly, 40 munici-
palities distributed over five geographic regions of the Netherlands were randomly selected
with probabilities proportional to their population size, and an age-stratified sample was
drawn from the population register. A total of 19,781 persons were invited to complete a ques-
tionnaire and donate a blood sample. Serum samples and questionnaires were obtained from
6,382 participants. To exclude the interference of maternal antibodies, we restrict analyses to
sera from persons older than 6 months (6,215 samples). We further select Dutch persons and
migrants of Western ethnicity to preclude confounding by ethnicity (5,179 samples) and strat-
ify the data by sex [21], yielding 2,842 and 2,337 samples from female and male participants,
respectively. The data are available at github.com/mvboven/cmv-serology.
Antibody assay
We use the ETI-CYTOK-G PLUS (DiaSorin, Saluggia, Italy) Elisa to detect CMV-specific IgG
antibodies. The assay yields continuous measurements (henceforth called ‘antibody concentra-
tion’). A small number of samples is right-censored (140 persons). We perform a Box-Cox
transformation of the data (λ = 0.3), yielding a distribution of low antibody concentrations
(-2.8< x-0.5) that is approximately normal. According to the provider of the assay, samples
with (transformed) measurement lower than -0.8 U/ml should be considered uninfected,
while samples with measurement greater or equal than -0.8 U/ml should be classified as
infected. Right-censoring is applied to the 140 samples above the upper limit of 3.41 U/ml. The
data with model fit (see below) are shown in Fig 1.
Mixture model
The data are analyzed statistically using a mixture model with sex- and age-specific mixing
functions. We distinguish three distributions, describing samples of low (susceptible, S), inter-
mediate (latently infected, L), and high (latently infected with increased antibodies, B) anti-
body concentrations. The L and B distributions are modeled using normal distributions with
means and standard deviations independent of age and sex. The S distribution is modeled by a
mixture of a spike and a normal distribution (an inflated normal distribution), as there appears
a spike at -2.91 U/ml in the data (263 persons). In this way, samples with concentration at the
spike belong to the susceptible component with probability 1.
We model the probability of each of the three outcomes in terms of log-odds, taking the
probability of being in the S component as reference. This allows us to write the log-odds of
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being in component L or B as linear functions of age and sex. The design matrix of the result-
ing multinomial logistic model consists of natural cubic splines with interior knots at 20, 40
and 60 years and boundary knots at 0 and 80 years. Hence, the mixing functions (prevalences)
have flexible shape, which allows these to be optimally informed by the data. In the results, sex
is put in the model as main effect, as analyses show no improvement in fit when including age
by sex interaction.
We estimate parameters in a Bayesian framework using R and JAGS [28, 29]. Non-informa-
tive normal prior distributions are set on the means of the three component distributions
(N ð0; 0:001Þ) (mean and precision). Label switching is prevented by prior ordering of the
means. The precisions of the components are given flat Gamma prior distributions (Γ(0.5,
0.005)). The spline parameters are also given non-informative normal prior distributions
(N ð0; 0:001Þ). We apply a QR-decomposition to the design matrix to improve mixing and
run 10 MCMC chains in parallel, yielding a total of 10,000 samples. We apply an 1/10 thinning
to give a well-mixed 1,000 samples from the posterior distribution.
Fig 1. Data and model fit. Data (histograms) and model fit (lines) of IgG antibody measurements by age
group and sex. Left- and right-hand panels show results for females (purple) and males (brown), respectively.
The leftmost bars at -2.9 contain samples that are assumed uninfected, and the rightmost bars at 4.5 contain
samples that are right-censored (with concentration >3.41 U/ml; Methods). Insets show the age group and
number of samples.
https://doi.org/10.1371/journal.pcbi.1005719.g001
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Transmission model and scenarios
Next to the mixture model analyses, we estimate parameters of transmission models to investi-
gate the ability of different transmission hypotheses explaining the data. To facilitate compari-
son between transmission models, take the medians of the estimated mixture distributions as
input. In line with the above, we focus on a sex- and age-structured model in which persons
are probabilistically classified as uninfected (S), latently infected (L), and latently infected after
reactivation or re-infection (B). As the infectious period is short relative to the lifespan of the
host (weeks versus decades), the infectious periods are modeled implicitly using the short-dis-
ease approximation [30]. Further, we focus on the endemic equilibrium of the transmission
model so that all variables are time-independent [30, 31]. Fig 2 shows a schematic of the
model. For sexes i 2 {♀,♂}, the differential equations for the age-specific relative frequencies
S(a), L(a), and B(a) (S(a) + L(a) + B(a) = 1) are given by
dSiðaÞ
da
¼   l
i
ðaÞSiðaÞ
dLiðaÞ
da
¼ l
i
ðaÞSiðaÞ   ðriðaÞ þ z liðaÞÞLiðaÞ
dBiðaÞ
da
¼ ðriðaÞ þ z liðaÞÞLiðaÞ ;
ð1Þ
with forces of infection
l
i
ðaÞ ¼
X
j2f♀;♂g
Z M
0
cijða; a0Þðb1l
j
ða0ÞSjða0Þ þ b2ðr
jða0Þ þ zljða0ÞÞLjða0ÞÞda0 : ð2Þ
In Eqs (1) and (2), zλj(a) and ρj(a) are the age-specific re-infection and reactivation rates, z
is the susceptibility to re-infection of latently infected persons relative to the susceptibility of
uninfected persons (0 z 1), cij(a, a0) represents the contact rate between persons of age a0
and sex j, and those of age a and sex i [32, 33], β1 and β2 are proportionality parameters deter-
mining the transmissibility of primary infection and reactivation/re-infection, and M is the
maximum age. As the data do not extend beyond 80 years we take M = 80 years. Notice that
λj(a)Sj(a) and (ρj(a) + z λj(a))Lj(a) are the incidence of primary infection and the incidence of
reactivation and re-infection, so that β1λ
j(a)Sj(a) and β2(ρj(a) + z λj(a))Lj(a) are the infectious
output generated by primary infection and reactivation/re-infection, respectively [30].
As in earlier studies, contact rates are hard-wired into the model using data on social con-
tact patterns, thereby adopting the social contact hypothesis [32–34]. Here we use the mixing
matrix based on reported physical contacts [32]. The discretized contact function and demo-
graphic data are available at github.com/mvboven/cmv-serology.
Fig 2. Schematic of the transmission model. Si(a) denotes the proportion of uninfected persons of age a
and sex i (i 2 {♀,♂}), and Li(a) and Bi(a) are the corresponding proportions of infected persons without and
with increased antibodies, respectively. The infection and re-infection rates are given by λi(a) and zλi(a), and
the reactivation rates are given by ρi(a). We consider model scenarios with and without reactivation/re-
infection in the B compartment (i.e. including or excluding the loop to the right of B).
https://doi.org/10.1371/journal.pcbi.1005719.g002
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Below, we consider a suite of simplifications and variations of the full model specified by
Eqs (1) and (2). In the simplifications, we assume that (i) there is no re-infection (z = 0), (ii)
there is no reactivation (ρi(0) = 0), or (iii) reactivation and re-infection are not infectious (β2 =
0). We also consider a variation of the model in which re-infection and reactivation do not
only occur upon transition from L to B, but also in the B compartment. In these models the
infectious output generated by reactivation and re-infection in Eq (2) (β2(ρj(a0) + zλj(a0))Lj(a0))
is replaced by β2(ρj(a0) + zλj(a0))(Lj(a0) + Bj(a0)).
Solution and discretization
The differential equations can be solved in terms of the forces of infection using the variation
of constants method. Here we assume, based on results of the mixture model, that a non-negli-
gible fraction of infants is infected in the first six months of life and the fraction infected is
equal in female and male infants [21]. Hence, we have S♀(0) = S♂(0) = S0, L♂(0) = L♀(0) = 1 −
S0, and B♀(0) = B♂(0) = 0 as initial conditions, and the solution of (1) is given by
SiðaÞ ¼ Si
0
e 
R a
0
lðtÞdt
LiðaÞ ¼ ð1   Si
0
Þe 
R a
0
rðtÞþzlðtÞdt
þ Si
0
R a
0
lðtÞe 
R t
0
lðt0Þdt0  
R a
t
rðt0Þþzlðt0Þdt0dt :
ð3Þ
Insertion of Eq (3) in Eq (2) yields two integral equations for the age-specific forces of infection
in females and males [34–37]. These equations cannot be solved explicitly in general. It is pos-
sible, however, to solve the equations for specific functions.
Here, we assume that reactivation and contact rates are constant on certain predefined age-
intervals. From Eq (2), it then follows that the force of infection is piecewise constant as well.
Throughout, we consider age intervals of fixed size Δa = 5 years, so that the limits of the n =
M/Δa = 16 age classes are defined by the vector a = (0, Δ a, 2Δ a, . . ., nΔ a). Hence, the j-th
class (j = 1, . . ., n) contains all persons with age in the interval [a[j], a[j + 1]), where a[j] denotes
the j-th element of a. Subsequently, the forces of infection λi(a) and reactivation rates ρi(a) are
replaced by their counterparts l
i
j and r
i
j. Similarly, S
i(a), Li(a), and Bi(a) at the borders of the
age-intervals are given by Sij, L
i
j, and B
i
j. Insertion in Eq (3) and integrating over the (constant)
rates yields
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Þ
;
ð4Þ
where i 2 {♀,♂} and Bij ¼ 1   S
i
j   L
i
j. Insertion of Eq (4) in Eq (2) and making use of the fact
that the cumulative incidences of infection and reactivation/re-infection in age class j are given
by
R a½jþ1
a½j
l
i
ðaÞSiðaÞda ¼ Siða½jÞ   Siða½jþ1Þ and B
i(a[j + 1]) − Bi(a[j]), yields 32 equations (16 per
sex) for the 32 forces of infection.
Estimation and model selection
As in the mixture model with spline mixing parameters, the log-likelihood of each observation
is given by a mixture distribution, where the spline functions are replaced by Si(a), Li(a), and
Bi(a). For instance, the likelihood contribution of a sample with antibody measurement c in a
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person of sex i and age a is given by
SiðaÞfSðcÞ þ LiðaÞfLðcÞ þ BiðaÞfBðcÞ ;
where Si(a), Li(a), and Bi(a) are the age specific prevalences in sex i, and fS(c), fL(c), and fB(c)
are the densities of the mixture distributions at antibody concentration c.
In both sexes, reactivation rates are modeled by piecewise constant functions with steps at
20 and 50 years, i.e. with rates that are constant on the intervals [0, 20), [20, 50), and [50, 80)
years. Hence, the reactivation rates are characterized by three parameters in each sex, viz.
ri
½0;20Þ
, ri
½20;50Þ
, and ri
½50;80Þ
(i 2 {♀,♂}).
Bayesian parameter estimates are obtained using Markov chain Monte Carlo (MCMC). Ini-
tially, results were obtained using tailored Mathematica code, using a single-component
random walk metropolis algorithm while solving the consistency equations for the forces of
infection using a Quasi-Newton (secant) method. As this became exceedingly slow for specific
models, we recoded the models using Hamiltonian Monte Carlo with Stan (mc-stan.org).
Here, the discretized equations for the forces of infection (2) are solved by specifying that the
differences between the left- and right-hand sides are small, and approximately N ð0; 10  4Þ
(mean and scale) distributed. Cross-checking of the two methods yielded very similar results.
All programs are available at github.com/mvboven/cmv-serology.
Prior distributions of the parameters are as follows: b1  N ð0:1; 10Þ (mean and scale),
b2  N ð0:1; 10Þ, z  Uð0; 1Þ, mr  N ð0; 10Þ, 1=sr  N ð0; 10Þ, and rix  N ðmr; srÞ for all i
and x. Whenever applicable, distributions are truncated to be positive. With these prior
parameter distributions, the joint posterior distribution is strongly dominated by the data. Ten
chains of 3,000 iterations are run in parallel, of which the first 500 iterations (warmup) are dis-
carded. We apply 1/5 thinning, yielding a total of 5,000 samples per model scenario. For all
parameters, effective sample sizes usually lie between 3,000 and 4,500. Convergence of chains
is assessed visually, and by assessment of the empirical variance within and between chains
[38]. To prevent the occurrence of divergent transitions we set ADAPT_DELTA = 0.99.
Parameter estimates and bounds of credible intervals are represented by 2.5, 50, and 97.5 per-
centiles of the posterior samples. Results are usually obtained in 1-3 hours on a personal
computer.
Model selection is based on WAIC, a measure for predictive performance, and WBIC, a
measure for identifying the most likely model generating the data [39–41]. WAIC is obtained
directly from the posterior likelihood using the R-package LOO (cran.r-project.org). WBIC is
calculated in a separate run as the average log likelihood over the posterior samples, using a
sampling ‘temperature’ determined by the number of observations [39].
Results
Classification
Fig 1 presents the data stratified by sex and age, with fit of the statistical model. The data and
model fit show peaks at low antibody measurements (-2.9 U/ml and-2 U/ml), corresponding
to uninfected persons (denoted by S). In both sexes, there is a third peak at higher measure-
ments (1-3 U/ml) that shifts to higher values with increasing age. This peak is composed of
persons who are infected (denoted by L) and persons who are infected with high antibody con-
centrations (denoted by B). Overall, the model appears to describe the data well.
This is confirmed in Fig 3, which shows the estimated components of the mixture distribu-
tion and diagnostic characteristics of the classification. The component distribution of unin-
fected persons hardly overlaps with the two component distributions for infected persons,
Infectious reactivation of cytomegalovirus
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while there is some overlap between the distributions of infected persons. This can be made
more precise using detection theory. Specifically, in Fig 3 we graph the specificity Sp (the prob-
ability of correctly classifying a negative subject) and sensitivity Se (the probability of correctly
classifying a positive subject) in a receiver operating characteristic (ROC) graph with antibody
concentration specifying a cut-off for binary classification as parameter [42–44]. Subsequently,
we use the maximal Youden index (i.e. max(Se + Sp − 1)) to choose an optimal cut-off, and
find that classification of persons as uninfected versus infected is near perfect (Youden index:
0.97, at cut-off -0.70 U/ml), while classification of persons with high antibody concentrations
is good (Youden index: 0.71, at cut-off 1.81 U/ml). These results show that the classification is
supported by the data (i.e. has high probability yielding an informed decision).
We further investigate whether mixture models with fewer or more components are able to
provide an even better description of the data, and found that a model with two mixture com-
ponents does not perform well (ΔWAIC = 300.2 in favor of the three-component mixture dis-
tribution), while performance of models with four components depends sensitively on choice
of prior distribution of the fourth distribution, and often yields broad posterior antibody distri-
butions with small estimated prevalence that overlap with the other three component distribu-
tions. Hence, a mixture model with three components gives an optimal description of the data.
Prevalence estimation
Fig 4 shows the estimated prevalences in females and males as a function of age [42–44]. The
prevalence of uninfected persons decreases gradually with age, from approximately 0.80 in
infants (females: 0.81, 95%CrI: 0.77-0.85; males: 0.80, 95%CrI: 0.76-0.84) to 0.27 (95%CrI:
0.22-0.34) and 0.38 (95%CrI: 0.32-0.45) at 80 years in females and males, respectively. In both
females and males the latently infected prevalence remains approximately constant, ranging
from 0.15 to 0.20 in females and from 0.18 to 0.28 in males. In contrast, the prevalence of per-
sons with increased antibodies increases strongly with age, especially in females. In fact, the
Fig 3. Classification of samples. Shown are the estimated components of the mixture distribution using the
parameter posterior medians (left-hand panel; blue: susceptible; purple: infected; red: infected with increased
antibody concentration), and receiver operating characteristic of binary classifications taking these estimates as
ground truth (right-hand panel). The maximal Youden index for classification of uninfected versus infected
persons is 0.97 at antibody concentration -0.70 U/ml, with sensitivity 0.99 and specificity 0.98. This value
corresponds well with the threshold for infection of -0.8 U/ml provided by the supplier of the assay. The maximal
Youden index for classification of persons with increased antibody concentration is 0.71 at antibody
concentration 1.81 U/ml, with sensitivity 0.84 and specificity 0.87.
https://doi.org/10.1371/journal.pcbi.1005719.g003
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prevalence of persons with increased antibodies increases from 0.09 (95%CrI: 0.06-0.13) at 20
years to 0.57 (95%CrI: 0.47-0.67) at 80 years in females, and from 0.04 (95%CrI: 0.03-0.07) to
0.37 (95%CrI: 0.28-0.46) in males. Hence, in older persons the prevalence of persons with
increased antibodies is 54% (or 20 per cent points) higher in females than in males.
Of particular interest is the prevalence of infection in females of childbearing age, as this
group is at risk of transmission to the fetus or newborn. Using the above analyses, we find that
Fig 4. Estimation of age- and sex-specific prevalence. Prevalence estimates are presented for females
(top panel) and males (bottom panel), and for classes of low (susceptible, blue), intermediate (latently
infected, purple), and high (latently infected with increased antibodies, red) antibody measurements. Shown
are 1,000 samples from the posterior distribution (thin lines) with posterior medians (bold lines). Dots indicate
the fraction of samples that would be classified as uninfected with the cut-off specified by the supplier of the
assay. The number of samples per 1-year age group is approximately 35 (females) and 30 (males).
https://doi.org/10.1371/journal.pcbi.1005719.g004
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the prevalence of infection (i.e. the combined prevalence in the L and B compartments) is 0.30
(95%CrI: 0.27-0.33) in 20-year-old females and 0.42 (95%CrI: 0.39-0.46) in 40-year-old
females. If we combine these figures with the observation that approximately 20% of children
are infected at six months of age, and that less than 5% of children in the Netherlands in 2007
had a mother under 20 years or over 40 years, we deduce that the probability of perinatal trans-
mission could be between 0.20/0.42 = 0.48 and 0.20/0.30 = 0.67, with the exact figure depend-
ing on the distribution of ages at which mothers give birth. In addition, one could envisage
that the highest risk of (severe) infection of the fetus or newborn is when mothers are infected
or experience a reactivation episode. The estimated rates at which susceptible females of 20
and 40 years are infected are 0.0055 per year (95%CrI: 0.0036-0.0077) and 0.0092 per year
(95%CrI: 0.0069-0.011) per year, respectively. The rates at which latently infected females of 20
and 40 years are re-infected or experience a reactivation episode are of similar magnitude, and
are estimated at 0.0059 per year (95%CrI: 0.0038-0.0086) and 0.0093 per year (95%CrI: 0.0064-
0.012), respectively. The overall rates of infection, reactivation, and re-infection in 20 and 40
year-old females are given by the sum of the above estimates, and are approximately 1% and
2% per year, respectively.
Estimation of reactivation and re-infection rates
To evaluate the ability of different transmission hypotheses explaining the data, and to obtain
parameter estimates that have a biological interpretation, we analyzed the data with transmis-
sion models. A comparison of model scenarios based on the information criteria WAIC and
WBIC is given in Table 1. Overall, the analyses show that models with the possibility of multi-
ple infectious reactivations perform best (Models E and F; lowest WAIC and WBIC), that
models with at most one infectious reactivation perform worse (Models A and B; ΔWAIC and
ΔWBIC10 − 15), and that models without reactivation or with reactivation not being infec-
tious have very low support (Models C, D, and G). These results indicate that infectious reacti-
vation is key to adequately explain the data with transmission models. This is true in our
model with contact structure based on reported physical contacts [32], and also in an alterna-
tive model formulation that assumes a uniform contact structure (ΔWAIC = 151.9 in favor of
the model with reactivation over the model without reactivation and no re-infection).
Within the set of models with infectious reactivation there are only small differences
between models that do and do not incorporate re-infection (Model A versus Model B, and
Model E versus Model F). This indicates that while infectious reactivation is essential to
Table 1. Model selection of transmission scenarios.
Model Description WAIC ΔWAIC WBIC ΔWBIC
A Reactivation and re-infection 22156.2 13.0 22211.3 13.7
B No re-infection 22155.5 12.3 22209.4 11.8
C No reactivation 22363.6 220.4 22396.9 199.3
D Reactivation/re-infection not infectious 22215.3 72.1 22247.9 36.6
E Multiple reactivations/re-infections 22144.0 0.7 22197.6 0
F Multiple reactivations and no re-infection 22143.2 0 22198.4 0.8
G Multiple re-infections and no reactivation 22364.4 221.2 22396.8 199.2
For each of seven model scenarios we report the WAIC, a measure of predictive performance, and WBIC, a measure for the most likely model generating
the data. Also shown are the WAIC and WBIC differences with the best fitting model. Models E-G contain the possibility of multiple reactivation/re-infection
events in persons with increased antibody concentrations (the B compartment; cf. Fig 2).
https://doi.org/10.1371/journal.pcbi.1005719.t001
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adequately describe the data, the analyses are inconclusive with respect to whether or not
infectious re-infection should be included.
Fig 5 and Table 2 show parameter estimates of the model with highest statistical support (as
judged by WBIC). The preferred model (Model E) includes multiple reactivations and re-
infections, infectious reactivation, and infectious re-infection. In this model, the estimated
transmissibility of primary infection (β1) is much lower than the transmissibility of reactiva-
tion/re-infection (β2). In fact, the posterior median of β2 is more than an order of magnitude
larger than the posterior median of β1. Further, the relative susceptibility to re-infection (i.e.
the probability of re-infection in a contact that would lead to infection if the contacted person
were uninfected) has a broad posterior distribution, and cannot be estimated with meaningful
precision from the data (z^ ¼ 0:32; 95%CrI: 0.017-0.84). Similar findings are obtained in other
model scenarios, in particular Models A-B and E-F (Table 1).
Estimates of the reactivation rates are quantitatively close in models with high support
(Models E-F). Reactivation rates generally increase with increasing age, and are substantially
Fig 5. Parameter estimates. Shown are kernel-smoothed posterior distributions of the relative susceptibility to re-
infection (z), the transmissibility of primary infection (β1) and reactivation/re-infection (β2), and the reactivation rates
in persons aged 0-20 years (ρ[0,20), purple: females; brown: males), 20-50 years (ρ[20,50)), and 50-80 years (ρ[50
− 80)) of the transmission model with the possibility of multiple reactivations and re-infections (Model E in Table 1).
https://doi.org/10.1371/journal.pcbi.1005719.g005
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higher in females than in males. In the preferred model (Model E), the estimated reactivation
rate is 0.013 per year (95%CrI: 0.0042-0.021) in 0-20 year-old females, which increases to 0.021
per year (95%CrI: 0.013-0.029) in 20-50 year-old females, and then increases further to 0.028
per year (95%CrI: 0.017-0.040) in 50 + -year-old females (Table 2). The corresponding reacti-
vation rates in males are 0.0054 per year (95%CrI: 0.0035-0.013), 0.011 per year (95%CrI:
0.0035-0.018), and 0.013 per year (95%CrI: 0.0043-0.021). These estimates are slightly higher
and slightly more precise in the model without re-infection (Model F), and somewhat higher
in models with a single reactivation/re-infection event (Models A-B).
In the two models with highest support (Models E-F), estimates of the force of infection
increase from approximately 0.012-0.013 per year in the youngest age group to 0.014-0.017 per
year in 10-15 year-old girls (Fig 6). Owing to the slightly higher contact rates in females than
in men, the estimated force of infection is usually slightly higher in females than in males in
the age groups 10-25 years [32]. In older age groups, estimates of the forces of infection
decrease to lower values (0.01 per year). Noteworthy, the extreme age-specific differences in
the force of infection usually observed for directly transmitted infectious diseases, with high
infection rates in children and much lower rates in adults, are much less pronounced here due
to infectious reactivation in older age strata combined with age-assortative mixing [32, 34, 35].
In models with re-infection, estimates of re-infection rate (zλi(a)) are considerably smaller
than estimates of the reactivation rates (ρi(a)) because the estimated forces of infection (λi(a))
are usually lower than the reactivation rates, especially in females (Fig 6). Hence, re-infection
contributes little to boosting of the antibody concentrations in those age groups where most of
the boosting occurs (>20 years; Fig 4). In fact, in adult females it is not uncommon that the
reactivation rate is more than an order of magnitude higher than the estimated re-infection
rate (log10(ρ♀(a)/(zλ♀(a)))> 1).
Discussion
Our study of population-wide serological data shows that IgG antibody concentrations contain
a wealth of information on the transmission dynamics of CMV. Specifically, the analyses reveal
that (i) the prevalence of CMV increases gradually with age such that at old age the majority of
Table 2. Parameter estimates of the transmission model.
Parameter Description Median 95%CrI
β1 Transmissibility of primary infection 0.0019 0.000081—0.0089
β2 Transmissibility of re-infection/reactivation 0.042 0.035—0.049
z Relative susceptibility for re-infection 0.32 0.017—0.84
r♀
½0;20Þ
Reactivation rate in 0-20 year old females (yr−1) 0.013 0.0042—0.021
r♀
½20;50Þ
Reactivation rate in 20-50 year old females (yr−1) 0.021 0.013—0.029
r♀
½50;80Þ
Reactivation rate in 50-80 year old females (yr−1) 0.028 0.017—0.040
r♂
½0;20Þ
Reactivation rate in 0-20 year old males (yr−1) 0.0054 0.0035—0.013
r♂
½20;50Þ
Reactivation rate in 20-50 year old males (yr−1) 0.011 0.0035—0.018
r♂
½50;80Þ
Reactivation rate in 50-80 year old males (yr−1) 0.013 0.0043—0.021
μρ Hyperparameter for the reactivation rate (mean) 0.015 0.0047—0.027
σρ Hyperparameter for the reactivation rate (sd) 0.010 0.0050—0.028
Parameters estimates (represented by posterior medians with 95% credible intervals) are shown of the transmission model with reactivation and re-infection
in the B compartment (model E). This model gives the best fit to the data, as judged by WBIC and WAIC (Table 1). For all parameters the potential scale
reduction factor Q is close to 1 (0.999 <Q < 1.001), and effective sample sizes of the parameters neff range from 3596 (β1) to 4457 (μρ).
https://doi.org/10.1371/journal.pcbi.1005719.t002
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persons in the Netherlands are infected; (ii) except for the very young, the prevalence of CMV is
systematically higher in females than in males. This is mainly due to a higher incidence of infec-
tion in adult women than in adult men of similar age; (iii) antibody concentrations in seroposi-
tive (i.e. infected) persons increase monotonically with age, especially in women; (iv) the above
findings (i)-(iii) cannot be explained by simple transmission models in which only primary
infection is infectious. This is caused by the fact that transmissibility of primary infection deter-
mines the rate at which age-specific prevalence increases; if transmissibility of primary infection
would be high then a high prevalence of infection is expected in children. In other words, the
fact that seroprevalence increases gradually with age puts an upper bound on the force of infec-
tion, and this in turn constrains the transmissibility of primary infection to low values.
While aforementioned findings (i)-(iii) have been noticed before in other settings ([1] and
references therein, [21]), our analyses are the first to provide precise estimates using a large
Fig 6. The force of infection and magnitude of reactivation relative to re-infection. The top panel shows
posterior estimates of the forces of infection in females and males in Model E (Table 1; purple: females;
brown: males). The bottom panel shows the log10 of the reactivation rates divided by the re-infection rates
(ρi(a)/zλi(a) with i 2 {♀,♂}). Results are shown for 250 samples from the posterior distribution.
https://doi.org/10.1371/journal.pcbi.1005719.g006
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population sample. Moreover, the results lead us to a new transmission hypothesis in which
infectious reactivation is a key driver of transmission of CMV in the population. Since several
other studies have found a gradual increase in seroprevalence [1], this explanation may not be
restricted to the Dutch situation, but hold in general. Underpinning this hypothesis, next to
the well-known observations of shedding of CMV in breast milk and cervical material in the
third trimester of pregnancy [45–47], detectable virus also has been found in healthy adults in
one study [24], while in another study CMV DNA has been detected in urine of the majority
of older persons [23].
The main implication is that the majority of CMV infections may not be caused by trans-
mission among children after primary infection, even though levels of shedding can be high in
infants [46, 48], but rather by older persons who go through one or more reactivation episodes.
This contrasts with common childhood diseases such as measles, mumps, rubella, and pertus-
sis. For these pathogens, infection in unvaccinated populations generally occurs at a young
age, and children are the drivers of transmission. It also contrasts with other herpes viruses
such as varicella zoster virus and Epstein-Bar virus for which well over 50% of the population
is infected at the age of 10 years [34]. It may be comparable with other herpes viruses such as
HSV1 and HSV2, which show a slowly increasing age-specific seroprevalence [49]. A corollary
is that persistence of CMV in the population is not possible with transmission from primary
infected persons only, and is dependent on infectious reactivation. Currently, we are focusing
on making this idea more precise by calculation of the basic reproduction number, and the
reproduction numbers of perinatal transmission, primary infection, and reactivation [50].
This will help put bounds on the relative contribution of each of the transmission routes.
With infectious reactivation and perinatal infection being putative drivers of transmission,
it is to be expected that elimination by vaccination may prove more difficult than for directly
transmitted pathogens, as it will require the pool of latently infected persons to dwindle to zero
by demographic turnover. This can take up to the lifetime of one generation, and perhaps
more if vaccination cannot prevent perinatal transmission to infants who are too young for
vaccination. Thus, a question is whether vaccination formulations and strategies exist that
minimize the probability of transmission to young infants. This is all the more of importance
as a main source of morbidity is by congenital infection, and the timescale on which reduc-
tions in congenital disease are expected determines the projected health impact of vaccination
[51]. In this context, next to the ability of a vaccine to prevent infection it may perhaps be
equally important that a vaccine is able to reduce the probability of reactivation. Such reduc-
tions are likely mediated by T-cell responses of the host, and several (but not all) vaccines
under development are expected to induce boosting of T-cell immune responses [52–54].
A number of limitations and assumptions deserve scrutiny. First, the transmission model
analyses assume that the population is in endemic equilibrium. For a single cross-sectional
data set such as the one considered in the present study this assumption is unavoidable if one
does not want to introduce additional parameters that cannot be estimated by the data. Reas-
suringly, the patterns of infection present in the serological data have been found in several
serological studies carried out in high-income countries over the past decades [1]. Also, no sys-
tematic patterns of increasing or decreasing seroprevalence over time have been found, and
this is further reason to believe that there have not been major changes in the epidemiology of
CMV over time [1]. Second, we assume that antibody measurements not only give information
on CMV infection status, but also whether or not reactivation or re-infection have taken place.
Unfortunately, there is no direct empirical evidence confirming or falsifying this assumption,
and this is an area where in-depth comparison of the infection and immune status of persons
with low and high antibody concentrations is urgently needed. Third, the analyses assume that
person-to-person transmission is proportional to observed human contact patterns [32, 33].
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Although this assumption is commonly made and has met with considerable success (e.g., [33,
44, 55, 56]), it is conceivable that transmission of CMV does not abide by the social contact
hypothesis, and that a more complex contact structure would be able to explain the patterns of
seroprevalence in a simple transmission model. To investigate the impact of the contact struc-
ture, we have analyzed transmission models with a uniform contact structure, and found that
models with infectious reactivation still provide the best fit to the data (ΔWAIC> 100;
Results). As a final limitation we would like to add that, in principle, it is conceivable that the
data can be explained alternatively by an intricate interplay between variation in the suscepti-
bility to infection in conjunction with age-specific variations in the strength of the antibody
response. Alas, evidence for or against this hypothesis is lacking.
Our inferential analyses indicate that the transmissibility of primary infection is much
lower than the transmissibility after reactivation. This seems to be at odds with the observation
that prolonged and high-level virus shedding can occur in bodily fluids after primary infection
in children [46, 47]. However, it could be that transitions from the infected class to the infected
class with increased antibodies are in effect not the result of a single reactivation or re-infection
event, but rather the result of multiple underlying reactivations or re-infections. If this were
true, as seems plausible, estimates of the reactivation and re-infection rates as well as the trans-
missibility of reactivation and re-infection should be interpreted as compound parameters that
take into account multiple reactivations and re-infections occurring over the lifetime of an
infected person.
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